EnFr
When women and adolescent girls have access to a variety of contraceptives, they are more likely to find and use a method that meets their needs and decide whether and when they want to become pregnant as well as how many children they want to have. And the addition of a new contraceptive method to the mix, or expanding geographic access to existing methods, can attract new contraceptive users and increase contraceptive prevalence. Data shows that when one additional contraceptive method is offered to at least half of a population, total contraceptive use can increase by four to eight percent.
Subcutaneous DMPA* (DMPA-SC) is an innovative injectable that can open up contraceptive access and choice to women and adolescent girls at the last mile and promote their empowerment and autonomy.
This resource library has been developed to provide comprehensive information on DMPA-SC evidence, country introduction experiences, service delivery and advocacy tools, and more for global- and country-level family planning implementers and decision-makers. We welcome your suggestions—if you have resources to submit, please use this submission form or contact us at FPoptions@path.org.
This site is hosted by the DMPA-SC Access Collaborative, an initiative led by PATH in partnership with JSI, Inc. The Access Collaborative provides data-driven technical assistance, coordination, resources, and tools to ensure that women and girls have increased access to DMPA-SC self-injection as part of an expanded range of contraceptive methods, delivered through informed choice programming. The Access Collaborative also facilitates learning exchange and dissemination within and among countries by sharing results and lessons learned, encouraging and facilitating discussion, troubleshooting challenges, and accelerating the adoption of best practices. This resource library was developed to help further those efforts.
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate. Brand name: Sayana Press.
Photo: PATH/Gabe Bienczycki